IgA Nephropathy, Lymphocyte Homing and IgA Class Switch

NCT ID: NCT01775527

Last Updated: 2016-08-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-02-28
• Study Completion Date: 2016-06-30

Brief Summary

IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world and it represents an important cause of end-stage kidney failure. This disease was described as a distinct entity in 1968 by J Berger and N Hinglais. The aetiology and the pathogenesis remain still obscure. Clinical observations and immunisation studies indicate that IgAN represents a dysregulation of the immune system, rather than an intrinsic renal abnormality. Twenty years ago, some authors proposed the mucosa-bone marrow axis to explain the pathogenesis of the disease. Mucosal IgA plasmocytes are displaced and take up residence in systemic sites. The unusual characteristics featured by the IgA produced by these cells (charge, size, glycosylation) drive their accumulation, deposition and mesangial activation characteristic of IgAN.

Evidence is emerging that altered lymphocyte homing may ultimately explain this aberrant localization.

Conditions

IgA Nephropathy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Blinding Strategy: NONE

Study Groups

blood test

Group Type: OTHER

blood test

Intervention Type: OTHER

Interventions

blood test

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Age > 18 and < 70 years
• IgA nephropathy documented by the kidney biopsy in the six months preceding the inclusion
• Glomerular filtration rate (MDRD formula as simplified) < 90 ml/mn and > 30 ml/mn/1,73 m2
• Consent form signed

Exclusion Criteria

• Patients with cirrhosis or chronic liver disease
• Patients with a history of Crohn's disease or celiac disease
• Patients who received treatment with corticosteroids or affiliates for six months
• Patients who received a live attenuated vaccine during the past 4 weeks
• Patients with a known infection such as HIV, hepatitis B or C
• Patients who presented with a serious infection during the last month
• Breastfeeding women
• Patients not affiliated with a social security scheme
• Under guardianship patient

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University Hospital, Limoges

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ahmed Boumediene, doctor

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Limoges

Locations

University Hospital, Limoges

Limoges, , France

Countries

France

Other Identifiers

I10 014

Identifier Type: -

Identifier Source: org_study_id